$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000082787117000004 Filed on May 08, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$76.79M	$29.59M
YoY Change	159.51%	-18.5%
Cost Of Revenue	$10.77M	$14.59M
YoY Change	-26.21%	145.28%
Gross Profit	$66.03M	$15.00M
YoY Change	340.13%	-50.59%
Gross Profit Margin	85.98%	50.7%
Selling, General & Admin	$18.58M	$12.13M
YoY Change	53.18%	204.26%
% of Gross Profit	28.14%	80.84%
Research & Development	$7.525M	$5.521M
YoY Change	36.3%	-12.16%
% of Gross Profit	11.4%	36.8%
Depreciation & Amortization	$196.0K	$140.0K
YoY Change	40.0%	1066.67%
% of Gross Profit	0.3%	0.93%
Operating Expenses	$44.10M	$30.49M
YoY Change	44.64%	87.98%
Operating Profit	$32.70M	-$897.0K
YoY Change	-3745.04%	-104.46%
Interest Expense	$27.00K	$0.00
YoY Change		-100.0%
% of Operating Profit	0.08%
Other Income/Expense, Net	-$24.00K	$20.00K
YoY Change	-220.0%	233.33%
Pretax Income	$32.67M	-$877.0K
YoY Change	-3825.43%	-104.36%
Income Tax	$9.748M	$19.00K
% Of Pretax Income	29.84%
Net Earnings	$22.92M	-$896.0K
YoY Change	-2658.48%	-104.55%
Net Earnings / Revenue	29.85%	-3.03%
Basic Earnings Per Share	$1.50	-$0.06
Diluted Earnings Per Share	$1.42	-$0.06
COMMON SHARES
Basic Shares Outstanding	15.26M shares	15.64M shares
Diluted Shares Outstanding	16.17M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.70M	$78.30M
YoY Change	-64.62%	-32.44%
Cash & Equivalents	$27.71M	$78.29M
Short-Term Investments
Other Short-Term Assets	$1.215M	$207.0K
YoY Change	486.96%	18.97%
Inventory	$3.015M	$7.761M
Prepaid Expenses
Receivables	$84.74M	$26.53M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$123.6M	$114.6M
YoY Change	7.81%	-11.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.796M	$2.869M
YoY Change	32.31%	2769.0%
Goodwill	$39.74M
YoY Change
Intangibles	$32.66M	$11.12M
YoY Change	193.81%
Long-Term Investments
YoY Change
Other Assets	$618.0K	$94.00K
YoY Change	557.45%	108.89%
Total Long-Term Assets	$101.2M	$14.08M
YoY Change	619.14%	9609.66%
TOTAL ASSETS
Total Short-Term Assets	$123.6M	$114.6M
Total Long-Term Assets	$101.2M	$14.08M
Total Assets	$224.8M	$128.7M
YoY Change	74.68%	-0.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.03M	$10.30M
YoY Change	84.82%	89.42%
Accrued Expenses	$15.40M	$19.56M
YoY Change	-21.28%	30.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$35.44M	$30.87M
YoY Change	14.8%	14.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$22.60M
YoY Change
Total Long-Term Liabilities	$22.60M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$35.44M	$30.87M
Total Long-Term Liabilities	$22.60M	$0.00
Total Liabilities	$58.00M	$36.40M
YoY Change	59.34%	34.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.735M	-$108.0M
YoY Change	-97.47%	20.03%
Common Stock	$16.00K	$15.00K
YoY Change	6.67%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$50.66M
YoY Change
Treasury Stock Shares	756.0K shares
Shareholders Equity	$166.8M	$92.32M
YoY Change
Total Liabilities & Shareholders Equity	$224.8M	$128.7M
YoY Change	74.68%	-0.95%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$22.92M	-$896.0K
YoY Change	-2658.48%	-104.55%
Depreciation, Depletion And Amortization	$196.0K	$140.0K
YoY Change	40.0%	1066.67%
Cash From Operating Activities	-$12.44M	$3.108M
YoY Change	-500.13%	-87.97%
INVESTING ACTIVITIES
Capital Expenditures	$676.0K	$804.0K
YoY Change	-15.92%	1769.77%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$3.100M
YoY Change	-100.0%	-91.39%
Cash From Investing Activities	-$676.0K	-$3.904M
YoY Change	-82.68%	-75.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$13.65M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$12.00M	$0.00
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$12.44M	$3.108M
Cash From Investing Activities	-$676.0K	-$3.904M
Cash From Financing Activities	-$12.00M	$0.00
Net Change In Cash	-$25.11M	-$796.0K
YoY Change	3054.52%	-101.22%
FREE CASH FLOW
Cash From Operating Activities	-$12.44M	$3.108M
Capital Expenditures	$676.0K	$804.0K
Free Cash Flow	-$13.11M	$2.304M
YoY Change	-669.1%	-91.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15298206	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2016Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2856000	USD
CY2017Q1	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	2154000	USD
CY2016Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	3528000	USD
CY2017Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1816000	USD
CY2016Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	7600000	USD
CY2017Q1	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	5036000	USD
CY2016Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	183000	USD
CY2017Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-3252000	USD
CY2017Q1	egrx	Number Of Products NumberOfProducts	5	product
CY2016Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1592000	USD
CY2017Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1062000	USD
CY2017Q1	egrx	Related Party Base Fee Due After Fifth Year RelatedPartyBaseFeeDueAfterFifthYear	0	USD
CY2017Q1	egrx	Related Party Base Fee Duein Fifth Year RelatedPartyBaseFeeDueinFifthYear	0	USD
CY2017Q1	egrx	Related Party Base Fee Duein Fourth Year RelatedPartyBaseFeeDueinFourthYear	0	USD
CY2017Q1	egrx	Related Party Base Fee Duein Second Year RelatedPartyBaseFeeDueinSecondYear	0	USD
CY2017Q1	egrx	Related Party Base Fee Duein Third Year RelatedPartyBaseFeeDueinThirdYear	0	USD
CY2017Q1	egrx	Related Party Base Fee Future Minimum Payments Remainderof Fiscal Year RelatedPartyBaseFeeFutureMinimumPaymentsRemainderofFiscalYear	2265000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14716000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	19027000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42194000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	84742000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25237000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15399000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2094000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1504000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9068000	USD
CY2017Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6989000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6003000	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2024000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	213872000	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220202000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4193000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2869000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4193000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	712000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2510702	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1522317	shares
CY2016Q4	us-gaap	Assets Assets	214320000	USD
CY2017Q1	us-gaap	Assets Assets	224820000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	109110000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	123572000	USD
CY2016Q1	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	6370000	USD
CY2017Q1	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	0	USD
CY2016Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	159000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	426000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22555000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1012000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1012000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22129000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79083000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78287000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52820000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27710000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-796000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-25110000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15890862	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16007789	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12767000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	10765000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	28643000	USD
CY2017Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	24431000	USD
CY2016Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2017Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4212000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	140000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	196000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.50
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.02
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.30
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	948000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1660000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17827000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2134000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3246000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3289000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3143000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3021000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33372000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32660000	USD
CY2016Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	1750000	USD
CY2017Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	39743000	USD
CY2016Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2017Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-877000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	32672000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9748000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6438000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4311000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	259000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42548000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4844000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9838000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6000000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	27000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7281000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	276000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-49000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	907469	shares
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33372000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	32660000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	27000	USD
CY2016Q1	us-gaap	Interest Expense Other InterestExpenseOther	1000	USD
CY2017Q1	us-gaap	Interest Expense Other InterestExpenseOther	27000	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	708000	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1153000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	2739000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	3015000	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1131000	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1862000	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	900000	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	162000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	162000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214320000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	224820000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40965000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	35438000	USD
CY2016Q1	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	2	patent
CY2016Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2404000	USD
CY2017Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	5936000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11998000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3904000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-676000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3108000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12436000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-896000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	22924000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-896000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	22924000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	30488000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	32696000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-897000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1832000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	44097000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	281000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	564000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	564000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	423000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1688000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	912000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	376000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1215000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	136000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	618000	USD
CY2016Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6000000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	25000000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13653000	USD
CY2016Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	482000	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	4850000	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	804000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	676000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	62000000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11357000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8105000	USD
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	135000	USD
CY2017Q1	us-gaap	Prepaid Insurance PrepaidInsurance	792000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1654000	USD
CY2017Q1	us-gaap	Prepaid Taxes PrepaidTaxes	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6500000	USD
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	62000000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1750000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2137000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3316000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3796000	USD
CY2017Q1	us-gaap	Purchase Obligation PurchaseObligation	20948000	USD
CY2017Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2017Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	20948000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5521000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7525000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25659000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2735000	USD
CY2016Q1	us-gaap	Royalty Expense RoyaltyExpense	1822000	USD
CY2017Q1	us-gaap	Royalty Expense RoyaltyExpense	7229000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	9469000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	36507000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14122000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15286000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	29591000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	76793000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12128000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18578000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2869000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4193000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3117
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3727
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0190
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0242
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0129
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0191
CY2017Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2137000	USD
CY2016Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	75000000.0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	151226000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	166827000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	566838	shares
CY2017Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	755983	shares
CY2016	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	566838	shares
CY2017Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	189145	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	37003000	USD
CY2017Q1	us-gaap	Treasury Stock Value TreasuryStockValue	50656000	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	37000000	USD
CY2017Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	13653000	USD
CY2017Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	13700000	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15636387	shares
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	16165361	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15636387	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15257892	shares
CY2017Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2016 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 15, 2017. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
CY2017Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-17-000004-index-headers.html	Edgar Link	pending
0000827871-17-000004-index.html	Edgar Link	pending
0000827871-17-000004.txt	Edgar Link	pending
0000827871-17-000004-xbrl.zip	Edgar Link	pending
egrx-20170331.xml	Edgar Link	completed
egrx-20170331.xsd	Edgar Link	pending
egrx-20170331_cal.xml	Edgar Link	unprocessable
egrx-20170331_def.xml	Edgar Link	unprocessable
egrx-20170331_lab.xml	Edgar Link	unprocessable
egrx-20170331_pre.xml	Edgar Link	unprocessable
egrx_q1x2017.htm	Edgar Link	pending
exhibit311q12017.htm	Edgar Link	pending
exhibit312q12017.htm	Edgar Link	pending
exhibit321q12017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2017 Q1 Form 10-Q Financial Statement

#000082787117000004 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2017 Q1 Form 10-Q Financial Statement

#000082787117000004 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx